INVA Stock Analysis: Buy, Sell, or Hold?
INVA - Innoviva, Inc. Common Stock
$22.91
0.25 (1.10%)
▲
5d:
+4.56%
30d:
-0.22%
90d:
+15.71%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 06, 2026
Smart Money Accumulation
INVA is down 6.2% this week, but smart money is accumulating calls. Top strike: $30 2026-04-17 with 1 OI. Call ratio: 100% View Scanner →
Strength: 8.1/10
Get Alerted When INVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: INVA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: INVA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$41.21
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$25.59
10.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: INVA is currently trading at $22.91, which is considered slightly high relative to its 30-day fair value range of $21.95 to $23.22. The stock's valuation (Forward PE: 11.3) is in line with its historical norms (10.4). At these levels, the market is pricing in 2.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, INVA is in a uptrend. The price is approaching resistance at $23.18. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: INVA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $36.40 (+58.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INVA is in a uptrend. The price is approaching resistance at $23.18. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: INVA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $36.40 (+58.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$21.95 -
$23.22
Company Quality Score
69/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 58.9% below Wall St target ($36.40)
- NEUTRAL: Market pricing in 2.6% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$21.95 -
$23.22
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$21.62
Resistance Level
$23.18
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.26
Wall Street Target
$36.40
(+58.9%)
Revenue Growth (YoY)
20.4%
Earnings Growth (YoY)
5478.9%
Profit Margin
32.8%
Valuation Premium vs History
+2.6% premium
PE vs Historical
11.3 vs 10.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.6%
(market-implied from PE analysis)
1-Year Target
$23.51
(+3%)
2-Year Target
$24.12
(+5%)
3-Year Target
$24.74
(+8%)
3-Yr Target (if PE normalizes)
(PE: 11→10)
PE COMPRESSION
$22.86
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 28.0%)
$95.36
(+316%)
Base:
(SPY PE: 11.3, Growth: 28.0%)
$48.03
(+110%)
Bear:
(PE: 9.6, Growth: 28.0%)
$40.83
(+78%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (13x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 13.37 | Current EPS (TTM): $1.66
Bull Case
$29.94
(+37%)
Analyst growth 22.6%, PE expands to 14.7
Base Case
$27.22
(+24%)
Market implied 22.6%, PE stable at 13.4
Bear Case
$15.10
(-31%)
Severe decline -20.0%, PE contracts to 11.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: March 30, 2026 6:38 PM ET
Data refreshes hourly during market hours. Next update: 7:38 PM
Data refreshes hourly during market hours. Next update: 7:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 52 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 49 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 57 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$43 | 56 HOLD |
Advanced INVA Option Strategies
Professional options setups generated by AI based on today's INVA price and gamma walls.
